MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2012

Jul 3, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SYNTA PHARMACEUTICALS CORP (SNTA)
CIK: 0001157601
Period of Report: 2012-07-01

Reporting Person: REARDON WILLIAM S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-07-01	Common Stock	A	3656	—	Acquired	17857	Direct
2012-07-01	Common Stock	A	1371	—	Acquired	19228	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-07-01	Director Stock Option (Right to Buy)	$5.47	A	10000	Acquired	2022-07-01	Common Stock (10000)	Direct

Footnotes

F1: Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as director of the Issuer on such date.

F2: Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as Chairman of the Audit Committee of the Board of Directors of the Issuer on such date.

F3: The option vests as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as a director of the Issuer on such date.